A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma

2024-515123-11-00 Protocol 2018-523-00US1 Human pharmacology (Phase I) - Other Ended

Start 5 Sep 2019 · End 26 Feb 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 2018-523-00US1

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 36
Countries 1
Sites 1

Lymphoma

Key facts

Sponsor
Hutchmed Ltd.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
5 Sep 2019 → 26 Feb 2025
Decision date (initial)
2024-11-11
Transition trial
Yes
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

External identifiers

EU CT number
2024-515123-11-00
EudraCT number
2018-004807-38
ClinicalTrials.gov
NCT03779113

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Lymphoma

VersionLevelCodeTermSystem organ class
21.0 LLT 10025632 Malignant lymphoma 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Hutchmed Ltd.

Sponsor organisation
Hutchmed Ltd.
Address
Building 4, 720 Cailun Road, China (Shanghai) Pilot Free Trade Zone 720 Cailun Road China (Shanghai) Pilot Free Trade Zone
City
Shanghai
Postcode
201203
Country
China

Scientific contact point

Organisation
Hutchmed Ltd.
Contact name
Clinical Trial Information

Public contact point

Organisation
Hutchmed Ltd.
Contact name
Clinical Trial Information

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Poland Ended 14 1
Rest of world
United States
22

Investigational sites

Poland

1 site · Ended
Medicover Integrated Clinical Services Sp. z o.o.
N/A, Ul. Stefana Batorego 18-22, 87-100, Torun

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Poland 2019-09-05 2019-11-04 2023-09-11

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-26 Poland Acceptable
2024-11-05
2024-11-11